Neurology India
Open access journal indexed with Index Medicus
  Users online: 455  
 Home | Login 
  About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe Etcetera Contact  
  Navigate Here 
 Search
 
  
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (852 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
 »  Abstract
 »  Materials and Me...
 » Results
 » Discussion
 » Conclusions
 »  References
 »  Article Figures
 »  Article Tables

 Article Access Statistics
    Viewed632    
    Printed6    
    Emailed0    
    PDF Downloaded26    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
ORIGINAL ARTICLE
Year : 2017  |  Volume : 65  |  Issue : 2  |  Page : 263-268

Imaging biomarker correlates with oxidative stress in Parkinson's disease


1 Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, Karnataka, India
2 Department of Neuroimaging and Interventional Radiology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, Karnataka, India
3 Department of Neurochemistry, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, Karnataka, India

Date of Web Publication10-Mar-2017

Correspondence Address:
Pramod Kumar Pal
Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bengaluru - 560 029, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/neuroindia.NI_981_15

Rights and Permissions

 » Abstract 

Background: While oxidative stress (OS) may be one of the crucial factors determining the initiation and progression of Parkinson's disease (PD), its correlation with gray matter (GM) atrophy is not known.
Aims: To determine the GM volume (GMV) changes using voxel-based morphometry (VBM) and correlation with OS marker serum malondialdehyde (MDA) in PD.
Materials and Methods: Seventy-two patients with PD were clinically evaluated and underwent magnetic resonance imaging (MRI) on a 3T MRI scanner using a 32-channel head coil. Lipid peroxidation product MDA levels were measured by spectrophotometry. MDA levels and regional GM differences using VBM were compared with 72 healthy controls.
Results: The mean age of the patients was 51.3 ± 10.6 years and that of controls was 50.8 ± 10.4 years. The mean age of onset of symptoms in PD was 45.2 ± 11.3 years. In PD, serum MDA level was significantly higher than that in controls (0.592 ± 0.89 μmol/l vs. 0.427 ± 0.055 μmol/l; P < 0.0001). Compared to controls, patients had greater regional GM atrophy in all the brain lobes (P < 0.001, uncorrected). A significant positive correlation was found between GMV and MDA in the caudate nucleus (CN) and posterior cingulate gyrus (PC) in the patient group (P < 0.001, uncorrected).
Conclusions: We observed GM atrophy in all major brain lobes of patients when compared to controls. Only in the patient group, a significant positive correlation was observed in CN and PC with MDA. These findings suggest that, even though the whole brain is affected in PD, some of the non-substantia nigra regions of the brain, such as CN, may have some differential compensatory mechanism, which are preserved from oxidative damage.


Keywords: Magnetic resonance imaging, malondialdehyde, oxidative stress, Parkinson's disease, voxel-based morphometry
Key Message:
In patients with PD, an increased level of serum malondialdehyde (a marker of oxidative stress formed by cellular membrane lipid peroxidation) is observed. This may positively correlate with the caudate nucleus and posterior cingulate gyrus vloume assessed on MRI. Therefore, although the whole brain is affected in PD leading to grey matter atrophy, some non-substantia nigra regions may possess differential compensatory mechanisms that preserve them from oxidative damage.


How to cite this article:
Naduthota RM, Bharath RD, Jhunjhunwala K, Yadav R, Saini J, Christopher R, Pal PK. Imaging biomarker correlates with oxidative stress in Parkinson's disease. Neurol India 2017;65:263-8

How to cite this URL:
Naduthota RM, Bharath RD, Jhunjhunwala K, Yadav R, Saini J, Christopher R, Pal PK. Imaging biomarker correlates with oxidative stress in Parkinson's disease. Neurol India [serial online] 2017 [cited 2017 May 23];65:263-8. Available from: http://www.neurologyindia.com/text.asp?2017/65/2/263/201878


Parkinson's disease (PD) is a progressive, neurodegenerative disorder, which affects more than 10 million people worldwide. Even though the disease onset varies between young, middle-aged, or elderly patients, it is more common observed in the elderly population. Clinical and pathological hallmarks of PD are characterized by dopaminergic cell loss in the substantia nigra (SN), which in turn leads to decreased level of dopamine in the striatum.[1] Even after several decades of research on PD, the etiology of the disease is not completely understood.[2] Environmental exposure, genetic susceptibility, and aging are some of the factors which play a crucial role in the pathogenesis of PD.[1],[3] Numerous cellular mechanisms such as oxidative damage, neuroinflammation, mitochondrial defect, formation of protein aggregates, and lysosomal dysfunction have been described in the pathogenesis of PD.[2],[4]

Oxidative stress (OS) is thought to play a pivotal role in both the genetic and sporadic forms of PD.[3] Reactive oxygen species damage biomolecules and result in protein aggregation, nucleic acid damage, and lipid peroxidation.[5] This creates a perilous state within the neuronal cell that leads to a gradual decline in physiological functions.[6],[7] Peroxidation of cellular membrane lipids leading to the production of toxic end products, such as malondialdehyde (MDA), poses a serious threat to membrane integrity resulting in cell death.[6] Postmortem studies on PD brains have reported increased levels of 4-hydroxynonenal, MDA, protein carbonyl changes, and DNA and RNA oxidation within the SN. MDA is known to be mutagenic and carcinogenic in nature.[5],[7] Changes in the plasma MDA level can be used as a potential peripheral biomarker to study OS in many pathological conditions. MDA serves as a principal aldehyde in thiobarbituric acid reactive substances (TBARS) assay.[8]

Voxel-based morphometry (VBM) is an automated, quantitative, operator independent, and unbiased neuroimaging technique.[9] VBM has been used to study various neurodegenerative disorders, movement disorders, epilepsy, multiple sclerosis, and schizophrenia.[10] One of the advantages of this technique is that it allows the study of significant gray matter volume (GMV) changes, in-vivo (local, endemic) at group level.[11] VBM analysis in PD patients has shown widespread GM loss in the frontal, parietal, and temporal cortical areas of the brain as a direct function of disease or as a consequence to it.[12] VBM has been widely used to study the association between GM atrophy with various motor and nonmotor features of PD.[13]

However, none of the studies have attempted to correlate serum oxidative markers with brain volume. The aim of this study is to investigate GM changes using VBM and correlate it with OS marker. We have correlated GMV in 72 patients with PD and 72 healthy controls with serum MDA levels. Our hypothesis is that PD patients may have raised MDA levels in comparison with healthy controls (HC) and MDA levels may inversely correlate with GMV in the patient group. Understanding molecular mechanisms of PD and correlating them with magnetic resonance imaging (MRI) findings are crucial for the better management of PD.


 » Materials and Methods Top


Seventy-two patients with PD fulfilling the UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria and 72 healthy age and gender-matched controls were prospectively recruited for the study over a period of 2 years (2012–2014). All patients were recruited from the Neurology Outpatient Department and Movement Disorder Clinic at a tertiary level neurology hospital. All patients were clinically examined and evaluated by a single movement disorder specialist. The stage of PD was assessed using the modified Hoehn and Yahr (H and Y) scale, and the degree of motor disability was assessed in the “ON” state using unified Parkinson's disease rating scale (UPDRS-III motor score). The motor scores of the right and left sides were calculated using the items 20–26 of the UPDRS-III score of each side. The patients were classified as 'Young onset' if the age of onset was <45 years. Controls with a family history of PD or Parkinsonian syndromes were excluded from the study. Information regarding the history of alcohol consumption, tobacco chewing, smoking, and diseases such as hypertension and diabetes were also obtained. All the participants were recruited after obtaining written informed consent. The study was approved by the institutional ethics committee.

Serum MDA, a measure of lipid peroxidation, was used as a marker of OS. Blood samples were collected into 5 ml vacutainers, without any anticoagulant, from all the participants by venipuncture after consumption of food. Blood samples were centrifuged after an hour at 2500 rpm for 10 minutes for separation of serum samples and stored immediately at −80°C until analysis. MDA levels were measured by a modified spectrophotometric method. In brief, 50 μl of serum sample or MDA working standard solution was added to 50 µl of trichloroacetic acid. Reaction mixture was centrifuged at 4000 rpm for 10 minutes at 4°C. Fifty microliter of supernatant was taken into a 10 ml test tube, and 1 ml of thiobarbituric acid (TBA) was added. Then, the samples were heated for 1 hr in a boiling water bath and cooled. This resulted in the formation of MDA-TBA adduct. Reaction mixture was extracted by the addition of n-butanol. Finally, the butanol phase was separated by centrifugation at 1500 rpm for 10 minutes. Supernatant was read at wavelengths of 540 nm for excitation and 590 nm for emission. Readings were compared with known concentration of MDA standards. All the samples were assayed in duplicates. The MDA levels were expressed in µmol/l.

MRI data were acquired on a 3T MRI scanner (Philips Achieva 3T, Philips Medical Systems, Netherlands) using a 32-channel head coil. MRI scan was performed in the ON-state of the patients to avoid movement artifacts. The same imaging protocol was used for all patients and healthy controls. T1-weighted images were acquired using a magnetization prepared rapid acquisition gradient echo sequence (repetition time = 8.2 ms, echo time = 3.8 ms, flip angle = 8°, field of view = 256 mm × 256 mm × 165 mm, 256 sagittal slices, voxel size = 1 mm × 1 mm × 1 mm). All the images were checked by a neuroradiologist for structural abnormalities before analysis.

Regional GM differences between the patient and control group were assessed using VBM. Data processing was performed with Statistical Parametric Mapping 8 (Wellcome Department of Cognitive Neurology, www.fil.ion.ucl.ac.uk/spm/software/spm8/) in MATLAB (Math Works, R2013a) setup using VBM8 toolbox. Images of two patients were excluded from the analysis due to poor quality. Before processing the data, each image was oriented into the standard anterior commissure-posterior commissure line. The preprocessing steps included spatial normalization into the Montreal Neurological Institute template and segmentation into GM, white matter, and cerebrospinal fluid. GM images were smoothened with an isotropic Gaussian kernel of 8 mm.

A two-sample t-test was performed between the PD group and control group to investigate the GM differences. Differences in the two groups were considered statistically significant if P was < 0.001 (uncorrected). Multiple regression analysis was performed to correlate GMV with MDA levels. The MRI result was presented uncorrected with a minimum cluster size of 100 voxels. Age, gender, and total intracranial volume (TIV) levels were considered covariates for group comparison. Age, gender, TIV, smoking, diabetes, hypertension, and alcoholism were used as covariates in both the groups for correlation analysis. In the patient group, along with these parameters, levodopa equivalent dose and duration of illness were also added as covariates.


 » Results Top


Clinical

The mean age of the patients was 51.4 ± 10.6 (22–71) years and that of controls was 50.6 ± 10.5 (20–73) years. The mean duration of illness was 5.1 ± 10.6 years in the patient group. The mean H and Y score in the patient group was 1.71 + 0.62, with 27 patients in stage 1 (37.5%), 38 patients in stage 2 (52.8%), and 7 patients in stage 3 (9.7%). The mean age of onset of symptoms in the PD group was 45.2 ± 11.4 years, with late-onset PD occurring in 72.2% (n = 52) and YOPD being 27.8% (n = 20) in the study group. There was a significant difference in the right and left UPDRS scores of patients with PD with right being more than left [7.9 ± 4.4 vs. 6.3 ± 5] (P < 0.0001) [Table 1]. Among the 72 patients, 44 (61.1%) patients reported that the tremor started on the right side, 26 (36.1%) patients reported it on the left side, and 2 (2.8%) patients reported bilateral tremors.
Table 1: Comparison of clinical, biochemical, and imaging characteristics between patients and controls

Click here to view


Malondialdehyde levels

In PD patients, serum MDA levels were significantly higher than in the controls. The mean MDA level was significantly higher in patients compared to controls (0.56 ± 0.1 µmol/l vs. 0.427 ± 0.055 µmol/l, P < 0.0001). To confirm repeatability and consistency of assay results, intraassay coefficient of variability (CV) and interassay CV was calculated (intraassay CV: 4% and intraassay CV: 5.7%).

Magnetic resonance imaging

There was no significant difference in total GMV between patients and controls (553.8 ± 55.6 vs. 562.25 ± 47.92, P = 0.18). However, regional GM analysis revealed focal decreases in volume in the patients involving all the major brain lobes including frontal, parietal, occipital, and temporal. In addition to this, GM atrophy was also observed in the anterior cingulate gyrus, parahippocampal gyrus, cingulate gyrus, and the cerebellar culmen and declive (P = 0.0001, uncorrected) [Table 2] and [Figure 1]. No significant correlations were found between GMV and the UPDRS-III score, H and Y score, or sidedness in the patient group.
Table 2: Voxel-based morphometry results with brain areas showing significant atrophy with patients with Parkinson's disease compared to controls

Click here to view
Figure 1: Voxel-based morphometry regions of decreased gray matter volume in patients with Parkinson's disease compared to controls

Click here to view


Correlation analysis

In both the patient and control groups, there was no significant correlation between MDA level and age or GMV. Our study did not find any correlation between MDA levels and UPDRS-III score, type of PD, and H and Y staging in the patient group.

Multiple regression analysis was performed between GMV and MDA levels in both groups. Age, gender, TIV, diabetes, hypertension, smoking, and alcoholism were considered to be covariates since these factors are known to affect the OS status. Only in the patient group, MDA levels showed a positive correlation with the volume of CN and the PC ( P< 0.000006, number of voxels = 2241) [Table 3].. There was no significant negative correlation between the MDA levels and VBM findings. In the control group, the MDA levels did not correlate significantly, either positively or negatively, with GMV of any brain region.
Table 3: Voxel-based morphometry results showing positive correlation between gray matter volume and malondialdehyde level in patients with Parkinson's disease (P<0.001, uncorrected)

Click here to view



 » Discussion Top


OS has been known to play a crucial role in nigrostriatal degeneration in many neurodegenerative disorders such as PD.[8] Brain is the second organ next to adipose tissue with the highest content of lipids. Polyunsaturated fatty acids in the brain are more susceptible to oxidative damage. Various markers of lipid peroxidation such as MDA, cholesterol, lipid hydroperoxide, isofurans, and acrolein are also found to be significantly elevated in PD.[14] MDA is a marker of lipid peroxidation and OS. It was significantly increased in our study, which supports the previous findings.[15],[16] A case-control study on 80 sporadic PD patients investigated by a thiobarbituric acid reactive substances (TBARS) assay showed increased lipid peroxidation level when compared to 29 healthy controls. This was confirmed by more studies in the Indian population.[8],[15],[17] High performance liquid chromatography (HPLC) analysis performed by Chen et al., among 211 PD patients and 135 controls also confirmed elevated levels of MDA in blood plasma.[18] Increased level of MDA suggests chronic OS in the brain. Even though MDA is a peripheral marker of OS, it does not have any diagnostic significance because many neurodegenerative disorders have elevated levels of MDA.[17]

While the pathology of PD is typically linked with the SN, the degeneration affects the entire brain.[19] In our study, GM atrophy was noted in bilateral medial frontal gyrus, right superior temporal gyrus, right cingulate gyrus, bilateral fusiform gyrus, right parahippocampal gyrus, left lentiform nucleus, cerebellar culmen and declive, right cuneus, left anterior cingulate, and right precentral gyrus in the patient group compared to the control group. Many studies have shown an associated atrophy of these regions with executive dysfunction, impaired social cognition, dementia, apathy, memory impairment, and psychosis in PD patients.[20],[21],[22]

It is established that SN is more prone to oxidative damage in PD.[23] However, the oxidative status of non-SN regions is not adequately studied. Interestingly, in our study, there was significant positive correlation between OS and non-SN regions such as the CN and PC. CN being part of striatum is the site for several pharmacologic interventions in PD. It is known to be associated with cognition, working memory, and multimodal information processing.[24],[25] 3D volume analysis using MRI documented decreased CN volume in the early stages of PD patients when compared to 15 age and gender-matched controls.[26] Apostolova et al., have also confirmed CN atrophy in PD patients with dementia.[27] Interestingly, some studies have reported increased GMV in CN of PD patients after practicing meditation for a long time.[28]

Postmortem studies of human PD brains have shown relatively lower level of OS and increased antioxidant levels in various non-SN regions such as CN, putamen, and frontal cortex.[23] In CN, increased protein oxidation and reduced lipid peroxidation have been reported. This study also documented increased level of total glutathione and astrocytic proliferation in these non-SN areas.[23] Another study from the same group demonstrated the effect of ageing on neurodegeneration. According to this study, oxidative damage, decreased levels of antioxidants, and mitochondrial function in SN with physiological aging make it more vulnerable to neurodegeneration in PD when compared to the non-SN regions.[29] Increase in carbonyl level, which is commonly used as a marker of oxidative protein injury has been observed in postmortem PD studies in CN, SN, putamen, and globus pallidus.[30] The cause of the variability among these findings is not known. The probable explanation could be oxidative status varying with duration and stages of PD. Only a few autopsy studies have documented changes in the antioxidant level in various regions of PD patients because in-vivo estimations are difficult.[8] The protective role played by CN in our study could indicate increased levels of antioxidants in non-SN regions. In-vivo analyses of such markers could help to prognosticate disease and predict drug response. In the present study, MDA level did not show significant negative correlation with any of the brain areas and, hence, OS may not be the only mechanism involved in widespread atrophy in PD.

Limitations

First, usage of peripheral serum biomarkers for correlation analysis in structural imaging has not been validated widely. More such studies would help in bridging the gap between imaging findings and clinical research. Second, though we have attempted to regress majority of factors, there exists a statistical concern because direct application of these findings to patient care will require randomized control studies. The use of region of interest-based analysis of SN, red nucleus, and other basal ganglia may provide complimentary information to VBM in addressing direct correlation. Finally, the uncorrected threshold was used for VBM analysis, which may include false positives; however, the significant cluster size obtained in our study reduces the possibility of chance findings.


 » Conclusions Top


We observed an increased level of MDA in patients with PD compared to matched controls which positively correlated with the volume of CN and PC, suggesting that, even though the whole brain is affected in PD, some of the non-SN regions of the brain may have differential compensatory mechanisms. This could preserve them from oxidative damage.

Financial support and sponsorship

This work was financially supported by Department of Biotechnology (DBT), Government of India. [Grant Number: NO. BT/PR14315/MED/30/474/2010].

Conflicts of interest

There are no conflicts of interest.

 
 » References Top

1.
Kovacic P, Somanathan R. Redox processes in neurodegenerative disease involving reactive oxygen species. Curr Neuropharmacol 2012;10:289-302.  Back to cited text no. 1
    
2.
Blandini F. Neural and immune mechanisms in the pathogenesis of Parkinson's disease. J Neuroimmune Pharmacol 2013;8:189-201.  Back to cited text no. 2
    
3.
Hwang O. Role of oxidative stress in Parkinson's disease. Exp Neurobiol 2013;22:11-7.  Back to cited text no. 3
    
4.
Tolleson CM, Fang JY. Advances in the mechanisms of Parkinson's disease. Discov Med 2013;15:61-6.  Back to cited text no. 4
    
5.
Lim KL, Zhang CW. Molecular events underlying Parkinson's disease-an interwoven tapestry. Front Neurol 2013;4:33.  Back to cited text no. 5
    
6.
Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson's disease. J Parkinsons Dis 2013;3:461-91.  Back to cited text no. 6
    
7.
Kong Q, Lin CL. Oxidative damage to RNA: Mechanisms, consequences, and diseases. Cell Mol Life Sci 2010;67:1817-29.  Back to cited text no. 7
    
8.
Vinish M, Anand A, Prabhakar S. Altered oxidative stress levels in Indian Parkinson's disease patients with PARK2 mutations. Acta Biochim Pol 2011;58:165-9.  Back to cited text no. 8
    
9.
Benninger DH, Thees S, Kollias SS, Bassetti CL, Waldvogel D. Morphological differences in Parkinson's disease with and without rest tremor. J Neurol 2009;256:256-63.  Back to cited text no. 9
    
10.
Whitwell JL. Voxel-based morphometry: An automated technique for assessing structural changes in the brain. J Neurosci 2009;29:9661-4.  Back to cited text no. 10
    
11.
Kassubek J, Juengling FD, Hellwig B, Spreer J, Lucking CH. Thalamic gray matter changes in unilateral Parkinsonian resting tremor: A voxel-based morphometric analysis of 3-dimensional magnetic resonance imaging. Neurosci Lett 2002;323:29-32.  Back to cited text no. 11
    
12.
Thaler A, Artzi M, Mirelman A, Jacob Y, Helmich RC, van Nuenen BF, et al.; LRRK2 Ashkenazi Jewish Consortium. A voxel-based morphometry and diffusion tensor imaging analysis of asymptomatic Parkinson's disease-related G2019S LRRK2 mutation carriers. Mov Disord 2014;29:823-7.  Back to cited text no. 12
    
13.
Shao N, Yang J, Shang H. Voxel wise meta-analysis of gray matter anomalies in Parkinson variant of multiple system atrophy and Parkinson's disease using anatomic likelihood estimation. Neurosci Lett 2015;587:79-86.  Back to cited text no. 13
    
14.
Sanders LH, Greenamyre JT. Oxidative damage to macromolecules in human Parkinson disease and the rotenone model. Free Radic Biol Med 2013;62:111-20.  Back to cited text no. 14
    
15.
Sharma A, Kaur P, Kumar B, Prabhakar S, Gill KD. Plasma lipid peroxidation and antioxidant status of Parkinson's disease patients in the Indian population. Parkinsonism Relat Disord 2008;14:52-7.  Back to cited text no. 15
    
16.
Hironishi M, Ueyama E, Senba E. Systematic expression of immediate early genes and intensive astrocyte activation induced by intrastriatal ferrous iron injection. Brain Res 1999;828:145-53.  Back to cited text no. 16
    
17.
Younes Mhenni S, Frih-Ayed M, Kerkeni A, Bost M, Chazot G. Peripheral blood markers of oxidative stress in Parkinson's disease. Eur Neurol 2007;58:78-83.  Back to cited text no. 17
    
18.
Chen CM, Liu JL, Wu YR, Chen YC, Cheng HS, Cheng ML, et al. Increased oxidative damage in peripheral blood correlates with severity of Parkinson's disease. Neurobiol Dis 2009;33:429-35.  Back to cited text no. 18
    
19.
Jubault T, Gagnon JF, Karama S, Ptito A, Lafontaine AL, Evans AC, et al. Patterns of cortical thickness and surface area in early Parkinson's disease. Neuroimage 2011;55:462-7.  Back to cited text no. 19
    
20.
Pan PL, Song W, Shang HF. Voxel-wise meta-analysis of gray matter abnormalities in idiopathic Parkinson's disease. Eur J Neurol 2012;19:199-206.  Back to cited text no. 20
    
21.
Summerfield C, Junqué C, Tolosa E, Salgado-Pineda P, Gómez-Ansón B, Martí MJ, et al. Structural brain changes in Parkinson disease with dementia: A voxel-based morphometry study. Arch Neurol 2005;62:281-5.  Back to cited text no. 21
    
22.
Nagano-Saito A, Washimi Y, Arahata Y, Kachi T, Lerch JP, Evans AC, et al. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 2005;64:224-9.  Back to cited text no. 22
    
23.
Mythri RB, Venkateshappa C, Harish G, Mahadevan A, Muthane UB, Yasha TC, et al. Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson's disease brains. Neurochem Res 2011;36:1452-63.  Back to cited text no. 23
    
24.
Lee JE, Cho KH, Song SK, Kim HJ, Lee HS, Sohn YH, et al. Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry 2014;85:7-16.  Back to cited text no. 24
    
25.
Jokinen P, Karrasch M, Bruck A, Johansson J, Bergman J, Rinne JO. Cognitive slowing in Parkinson's disease is related to frontostriatal dopaminergic dysfunction. J Neurol Sci 2013;329:23-8.  Back to cited text no. 25
    
26.
Lee SH, Kim SS, Tae WS, Lee SY, Choi JW, Koh SB, et al. Regional volume analysis of the Parkinson disease brain in early disease stage: Gray matter, white matter, striatum, and thalamus. AJNR Am J Neuroradiol 2011;32:682-7.  Back to cited text no. 26
    
27.
Apostolova LG, Beyer M, Green AE, Hwang KS, Morra JH, Chou YY, et al. Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia. Mov Disord 2010;25:687-95.  Back to cited text no. 27
    
28.
Pickut BA, Van Hecke W, Kerckhofs E, Marien P, Vanneste S, Cras P, et al. Mindfulness based intervention in Parkinson's disease leads to structural brain changes on MRI: A randomized controlled longitudinal trial. Clin Neurol Neurosurg 2013;115:2419-25.  Back to cited text no. 28
    
29.
Venkateshappa C, Harish G, Mythri RB, Mahadevan A, Bharath MM, Shankar SK. Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: Implications for Parkinson's disease. Neurochem Res 2012;37:358-69.  Back to cited text no. 29
    
30.
Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 1997;69:1326-9.  Back to cited text no. 30
    


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1], [Table 2], [Table 3]



 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow